The project aims to identify the most promising targets of humoral immunity, based on their important biological function, through a consortium-based effort. The project relies on the use of monoclonal antibodies as tools to disrupt critical parasite functions. For those antibodies that show the greatest capacity to disrupt critical parasite functions in preclinical studies (e.g., gliding motility, and hepatocyte invasion/traversal), target validation will be performed in clinical studies through passive monoclonal antibody administration, followed by controlled human malaria infection (CHMI). Protection from infection by an antibody (or antibody mixture) will trigger vaccine development for the corresponding antigen.